RSS feed

Publications (original articles or review articles) published in 2024 from OUS - Department of Gynaecological Oncology

38 publications found

Areklett EW, Hagen BI, Stubberud J, Fagereng E, Andersson S, Lindemann K (2024)
Digital goal management training for cognitive impairment in cervical cancer survivors-a randomized comparison study
J Cancer Surviv (in press)
DOI 10.1007/s11764-024-01701-4, PubMed 39576570

Birgisdóttir A, Myklebust TÅ, Bjørnslett M, Rognlien VW, Paulsen T, Dørum A (2024)
BRCA mutation testing and association with oncologic outcome and incidence of ovarian cancer in Norway
Int J Gynecol Cancer, 35 (2), 100029
DOI 10.1016/j.ijgc.2024.100029, PubMed 39971428

Bischof K, Cremaschi A, Eroukhmanoff L, Landskron J, Flage-Larsen LL, Gade A, Bjørge L, Urbanucci A, Taskén K (2024)
Patient-derived acellular ascites fluid affects drug responses in ovarian cancer cell lines through the activation of key signalling pathways
Mol Oncol, 19 (1), 81-98
DOI 10.1002/1878-0261.13726, PubMed 39245677

Bischof K, Holth A, Bassarova A, Davidson B (2024)
Expression of PRAME in high-grade serous carcinoma is associated with higher residual disease volume and Occludin expression
Pathol Res Pract, 266, 155787
DOI 10.1016/j.prp.2024.155787, PubMed 39709875

Casey NP, Kleinmanns K, Forcados C, Gelebart PF, Joaquina S, Lode M, Benard E, Kaveh F, Caulier B, Helgestad Gjerde C, García de Jalón E, Warren DJ, Lindemann K, Rokkones E, Davidson B, Myhre MR, Kvalheim G, Bjørge L, McCormack E, Inderberg EM, Wälchli S (2024)
Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16
J Immunother Cancer, 12 (4)
DOI 10.1136/jitc-2023-008179, PubMed 38604812

Cun HT, Bernard L, Lande KT, Lawson BC, Nesbakken AJ, Davidson B, Lindemann K, Fellman B, Sørlie T, Soliman PT, Eriksson AGZ (2024)
Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma
Gynecol Oncol, 189, 138-145
DOI 10.1016/j.ygyno.2024.07.677, PubMed 39126895

Dagher C, Bjerre Trent P, Alwaqfi R, Davidson B, Ellenson L, Zhou QC, Iasonos A, Mueller JJ, Alektiar K, Makker V, Kim S, Leitao MM, Abu-Rustum NR, Eriksson AGZ (2024)
Oncologic outcomes based on lymphovascular space invasion in node-negative FIGO 2009 stage I endometrioid endometrial adenocarcinoma: a multicenter retrospective cohort study
Int J Gynecol Cancer, 34 (10), 1485-1492
DOI 10.1136/ijgc-2024-005746, PubMed 39074932

Davidson B, Holth A, Lindemann K, Zahl Eriksson AG, Nilsen TA, Torgunrud A (2024)
Molecular characteristics of tubo-ovarian carcinosarcoma at different anatomic locations
Virchows Arch, 485 (6), 1053-1061
DOI 10.1007/s00428-024-03821-9, PubMed 38733380

Davidson B, Skeie-Jensen T, Holth A, Hausladen S (2024)
Stathmin is an Independent Prognostic Marker of Poor Outcome in Uterine Leiomyosarcoma
Int J Gynecol Pathol, 44 (1), 56-66
DOI 10.1097/PGP.0000000000001030, PubMed 38847524

Davidson B, Teien Lande K, Nebdal D, Nesbakken AJ, Holth A, Lindemann K, Zahl Eriksson AG, Sørlie T (2024)
Endometrial carcinomas with ambiguous histology often harbor TP53 mutations
Virchows Arch (in press)
DOI 10.1007/s00428-024-03912-7, PubMed 39235515

Denschlag D, Heitz F, Pfisterer J, Tutschkow D, Reuss A, Meier W, Harter P, Wimberger P, Mirza MR, Ray-Coquard I, Scambia G, Kim JW, Colombo N, Oaknin A, Sehouli J, Lindemann K, Lebreton C, Eichbaum M, Spiegelberg S, Woopen H, du Bois A (2024)
Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined analysis of four prospective trials of AGO-OVAR and ENGOT/GCIG collaborators
Int J Gynecol Cancer, 34 (12), 1914-1923
DOI 10.1136/ijgc-2024-005663, PubMed 39322609

Ferguson SE, Brotto LA, Kwon J, Samouelian V, Ferron G, Maulard A, Kroon C, Driel WV, Tidy J, Williamson K, Mahner S, Kommoss S, Goffin F, Tamussino K, Eyjolfsdottir B, Kim JW, Gleeson N, Tu D, Shepherd L, Plante M (2024)
Sexual Health and Quality of Life in Patients With Low-Risk Early-Stage Cervical Cancer: Results From GCIG/CCTG CX.5/SHAPE Trial Comparing Simple Versus Radical Hysterectomy
J Clin Oncol, 43 (2), 167-179
DOI 10.1200/JCO.24.00440, PubMed 39353164

Fotopoulou C, Eriksson AG, Planchamp F, Morice P, Taylor A, Sturdza A, Florin Coza O, Halaska MJ, Martinelli F, Armbrust R, Chargari C (2024)
European Society of Gynaecological Oncology expanded quality indicators and accreditation for cervical cancer management
Int J Gynecol Cancer, 34 (4), 480-490
DOI 10.1136/ijgc-2024-005293, PubMed 38395448

Kleppe A, Lindemann K, Kildal W, Tobin KAR, Pradhan M, Vlatkovic L, Isaksen MX, Danielsen HE, Askautrud HA, Kristensen GB (2024)
Prognostic and therapeutic implication of molecular classification including L1CAM expression in high-risk endometrial cancer
Gynecol Oncol, 192, 80-88
DOI 10.1016/j.ygyno.2024.11.005, PubMed 39549540

Krakstad C, Berg HF, Lindemann K, Halle MK (2024)
Frequency of ERBB2-Low Expression in Endometrial Cancer
JAMA Oncol, 10 (11), 1587-1588
DOI 10.1001/jamaoncol.2024.3660, PubMed 39235791

Kwon JS, McTaggart-Cowan H, Ferguson SE, Samouëlian V, Lambaudie E, Guyon F, Tidy J, Williamson K, Gleeson N, de Kroon C, van Driel W, Mahner S, Hanker L, Goffin F, Berger R, Eyjólfsdóttir B, Kim JW, Brotto LA, Pataky R, Yeung SST, Chan KKW, Cheung MC, Ubi J, Tu D, Shepherd LE et al. (2024)
Cost-effectiveness analysis of simple hysterectomy compared to radical hysterectomy for early cervical cancer: analysis from the GCIG/CCTG CX.5/SHAPE trial
J Gynecol Oncol, 35 (6), e117
DOI 10.3802/jgo.2024.35.e117, PubMed 39453395

La Russa M, Zapardiel I, Zalewski K, Laky R, Dursun P, Sukhin V, Lindquist D, Lindemann K (2024)
Assessment of palliative care training in gynaecological oncology: a survey among European Network of Young Gynae-Oncologists (ENYGO) members
BMJ Support Palliat Care, 15 (1), 104-107
DOI 10.1136/bmjspcare-2020-002233, PubMed 32958506

Ledermann JA, Matias-Guiu X, Amant F, Concin N, Davidson B, Fotopoulou C, González-Martin A, Gourley C, Leary A, Lorusso D, Banerjee S, Chiva L, Cibula D, Colombo N, Croce S, Eriksson AG, Falandry C, Fischerova D, Harter P, Joly F, Lazaro C, Lok C, Mahner S, Marmé F, Marth C et al. (2024)
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
Ann Oncol, 35 (3), 248-266
DOI 10.1016/j.annonc.2023.11.015, PubMed 38307807

Lindemann K, Kildal W, Kleppe A, Tobin KAR, Pradhan M, Isaksen MX, Vlatkovic L, Danielsen HE, Kristensen GB, Askautrud HA (2024)
Impact of molecular profile on prognosis and relapse pattern in low and intermediate risk endometrial cancer
Eur J Cancer, 200, 113584
DOI 10.1016/j.ejca.2024.113584, PubMed 38330767

Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, Acevedo A, Cvek J, Randall L, Pereira de Santana Gomes AJ, Contreras Mejía F, Helpman L, Akıllı H, Lee JY, Saevets V, Zagouri F, Gilbert L, Sehouli J, Tharavichitkul E, Lindemann K, Colombo N, Chang CL, Bednarikova M, Zhu H, Oaknin A et al. (2024)
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
Lancet, 404 (10460), 1321-1332
DOI 10.1016/S0140-6736(24)01808-7, PubMed 39288779

Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, Acevedo A, Sukhin V, Cloven N, Pereira de Santana Gomes AJ, Contreras Mejía F, Reiss A, Ayhan A, Lee JY, Saevets V, Zagouri F, Gilbert L, Sehouli J, Tharavichitkul E, Lindemann K, Lazzari R, Chang CL, Lampé R, Zhu H, Oaknin A et al. (2024)
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
Lancet, 403 (10434), 1341-1350
DOI 10.1016/S0140-6736(24)00317-9, PubMed 38521086

Luijten MMW, van Weelden WJ, Lalisang RI, Bulten J, Lindemann K, van Beekhuizen HJ, Trum H, Boll D, Werner HMJ, van Lonkhuijzen LRCW, Yigit R, Krakstad C, Witteveen PO, Galaal K, van Ginkel AA, Bignotti E, Weinberger V, Sweegers S, Eriksson AGZ, Keizer DM, van de Stolpe A, Romano A, Pijnenborg JMA, European Network For Individualized Treatment In Endometrial Cancer (2024)
Hormone Receptor Expression and Activity for Different Tumour Locations in Patients with Advanced and Recurrent Endometrial Carcinoma
Cancers (Basel), 16 (11)
DOI 10.3390/cancers16112084, PubMed 38893205

Mirza MR, Bjørge L, Marmé F, Christensen RD, Gil-Martin M, Auranen A, Ataseven B, Rubio MJ, Salutari V, Luczak AA, Runnebaum IB, Redondo A, Lindemann K, Trillsch F, Ginesta MPB, Roed H, Kurtz JE, Petersson KS, Nyvang GB, Sehouli J (2024)
Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial
Gynecol Oncol, 192, 128-136
DOI 10.1016/j.ygyno.2024.12.003, PubMed 39657575

Mirza MR, Tandaric L, Henriksen JR, Mäenpää J, Christensen RD, Waldstrøm M, Lindemann K, Roed H, Auranen A, Akslen LA, Thomsen LCV, Lindberg SN, Madsen K, Bjørge L (2024)
NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer
Gynecol Oncol, 188, 103-110
DOI 10.1016/j.ygyno.2024.06.017, PubMed 38943691

Morice P, Scambia G, Abu-Rustum NR, Acien M, Arena A, Brucker S, Cheong Y, Collinet P, Fanfani F, Filippi F, Eriksson AGZ, Gouy S, Harter P, Matias-Guiu X, Pados G, Pakiz M, Querleu D, Rodolakis A, Rousset-Jablonski C, Stepanyan A, Testa AC, Macklon KT, Tsolakidis D, De Vos M, Planchamp F et al. (2024)
Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and ESGE
Lancet Oncol, 25 (11), e602-e610
DOI 10.1016/S1470-2045(24)00262-6, PubMed 39216500

Nikolova T, Bilir E, Bizzarri N, Fotopoulou C, van Gorp T, Kacperczyk-Bartnik J, Razumova Z, Strojna AN, Eriksson AG, Pakiz M, Mirza MR, Fagotti A, Concin N (2024)
Gender equality, diversity, and inclusion among gynaecologic oncologists: European Network of Young Gynae Oncologists (ENYGO)-European Society of Gynaecological Oncology (ESGO) project
Int J Gynecol Cancer, 34 (11), 1685-1690
DOI 10.1136/ijgc-2024-005697, PubMed 39395820

Os SS, Skipar K, Skovlund E, Hompland I, Hellebust TP, Guren MG, Lindemann K, Nakken ES (2024)
Survival prediction in patients with gynecological cancer irradiated for brain metastases
Acta Oncol, 63, 206-212
DOI 10.2340/1651-226X.2023.34899, PubMed 38647023

Plante M, Kwon JS, Ferguson S, Samouëlian V, Ferron G, Maulard A, de Kroon C, Van Driel W, Tidy J, Williamson K, Mahner S, Kommoss S, Goffin F, Tamussino K, Eyjólfsdóttir B, Kim JW, Gleeson N, Brotto L, Tu D, Shepherd LE, CX.5 SHAPE investigators, CX.5 SHAPE Investigators (2024)
Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer
N Engl J Med, 390 (9), 819-829
DOI 10.1056/NEJMoa2308900, PubMed 38416430

Plante M, Mahner S, Sebastianelli A, Bessette P, Lambaudie E, Guyon F, Piek J, Smolders R, Tidy J, Williamson K, Hanker L, Goffin F, Tsibulak I, Eyjolfsdottir B, Gleeson N, Lee JY, Ke Y, Kwon JS, Ferguson SE, Shepherd L, Tu D (2024)
Minimally invasive compared to open surgery in patients with low-risk cervical cancer following simple hysterectomy: An exploratory analysis from the Gynegologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/SHAPE trial
Int J Gynecol Cancer, 35 (1), 100001
DOI 10.1016/j.ijgc.2024.100001, PubMed 39878257

Puco K, Fagereng GL, Brabrand S, Niehusmann P, Støre Blix E, Samdal Steinskog ES, Haug Å, Fredvik Torkildsen C, Oppedal IA, Meltzer S, Flobak Å, Johansson KAM, Bjørge L, Hjortland GO, Dalhaug A, Lund JÅ, Gilje B, Grønlie Cameron M, Hovland R, Falk RS, Smeland S, Giercksky Russnes HE, Taskén K, Helland Å, InPreD Consortium et al. (2024)
IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results
Acta Oncol, 63, 379-384
DOI 10.2340/1651-226X.2024.28322, PubMed 38779911

Rios-Doria E, Abu-Rustum NR, Glaser G, McGree M, Eriksson AG, Pham M, Soliman P, Ataseven B, Alektiar K, Zamarin D, Leitao ML, Mueller J (2024)
2009 International Federation of Gynecology and Obstetrics (FIGO) stage IIIA endometrial cancer: oncologic outcomes based on involvement of adnexa, serosa, or both
Int J Gynecol Cancer, 34 (10), 1580-1587
DOI 10.1136/ijgc-2024-005567, PubMed 39074930

Rios-Doria E, Nobre SP, Sassine D, Glaser G, Eriksson AG, Ataseven B, du Bois A, Makker V, Alektiar K, Leitao MM, Abu-Rustum NR, Mueller JJ (2024)
Impact of adjuvant therapy on oncologic outcomes in uterine-confined clear cell carcinoma of the endometrium
Gynecol Oncol, 190, 236-242
DOI 10.1016/j.ygyno.2024.08.019, PubMed 39243699

Rostami S, Rounge TB, Pestarino L, Lyle R, Fortner RT, Haaland ØA, Lie RT, Wiklund F, Bjørge T, Langseth H (2024)
Differential levels of circulating RNAs prior to endometrial cancer diagnosis
Int J Cancer, 155 (5), 946-956
DOI 10.1002/ijc.34951, PubMed 38733362

Sehouli J, Boer J, Brand AH, Oza AM, O'Donnell J, Bennett K, Glaspool R, Lee CK, Ethier JL, Harter P, Seebacher-Shariat V, Chang TC, Cohen PA, van Gorp T, Chavez-Blanco A, Welch S, Hranovska H, O'Toole S, Lok CAR, Madariaga A, Rauh-Hain JA, Perez Fidalgo A, Tan D, Michels J, Pothuri B et al. (2024)
How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting
Int J Gynecol Cancer, 34 (11), 1677-1684
DOI 10.1136/ijgc-2024-005982, PubMed 39496422

Skipar K, Hompland T, Lund KV, Lindemann K, Hellebust TP, Bruheim K, Lyng H (2024)
MRI-guided dynamic risk assessment in cervical cancer based on tumor hypoxia at diagnosis and volume response at brachytherapy
Radiother Oncol, 195, 110263
DOI 10.1016/j.radonc.2024.110263, PubMed 38556173

Stawiski K, Fortner RT, Pestarino L, Umu SU, Kaaks R, Rounge TB, Elias KM, Fendler W, Langseth H (2024)
Validation of miRNA signatures for ovarian cancer earlier detection in the pre-diagnosis setting using machine learning approaches
Front Oncol, 14, 1389066
DOI 10.3389/fonc.2024.1389066, PubMed 38983926

Sveen A, Johannessen B, Klokkerud SM, Kraggerud SM, Meza-Zepeda LA, Bjørnslett M, Bischof K, Myklebost O, Taskén K, Skotheim RI, Dørum A, Davidson B, Lothe RA (2024)
Evolutionary mode and timing of dissemination of high-grade serous carcinomas
JCI Insight, 9 (3)
DOI 10.1172/jci.insight.170423, PubMed 38175731

Van Gorp T, Cibula D, Lv W, Backes F, Ortaç F, Hasegawa K, Lindemann K, Savarese A, Laenen A, Kim YM, Bodnar L, Barretina-Ginesta MP, Gilbert L, Pothuri B, Chen X, Flores MB, Levy T, Colombo N, Papadimitriou C, Buchanan T, Hanker LC, Eminowicz G, Rob L, Black D, Lichfield J et al. (2024)
ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer
Ann Oncol, 35 (11), 968-980
DOI 10.1016/j.annonc.2024.08.2242, PubMed 39284383